The first 50 COVID-19 positive patients at the Department of Haemato-oncology, Faculty Hospital Ostrava in 2020
Authors:
O. Šušol 1; B. Hájková 1; J. Mihályová 1,2; M. Kaščák 1; J. Ďuraš 1,2; J. Zuchnická 1; H. Plonková 1; K. Hradská 1; T. Jelínek 1,2; M. Navrátil 1,2; K. Benková 1; L. Stejskal 1,2; Z. Kořístek 1,2; T. Popková 1; D. Buff 1; I. Demel 1; L. Muroňová 1; B. Dluhošová 1; L. Szeligová 1; L. Dudová 1; H. Zelená 2,3; J. Gumulec 1,2; R. Hájek 1,2
Authors‘ workplace:
Klinika hematoonkologie FN Ostrava
1; LF OU, Ostrava
2; Centrum klinických laboratoří, Zdravotní ústav se sídlem v Ostravě
3
Published in:
Transfuze Hematol. dnes,27, 2021, No. 4, p. 323-329.
Category:
Original Papers
doi:
https://doi.org/10.48095/cctahd2021323
Overview
Aim: The novel coronavirus (SARS-CoV-2) is a highly contagious disease with a significant mortality rate. Haematological patients are among those most at risk. We evaluate here the disease course, association between comorbidities and COVID-19 severity and seroconversion potential in 50 positive patients at our clinic. Methods: We performed 1,600 diagnostic PCR nasopharyngeal swabs over a period of 8 months. We introduced a set of preventive measures so as to protect our patients and personnel. In 50 COVID-19 positive patients, we closely evaluated the course of the disease, the impact of underlying risk factors and the principal haematological diagnoses. We also evaluated the potential for seroconversion in 15 COVID-19 positive patients. Results: Strict barrier measures, especially in patients undergoing autologous stem cell transplantation, have been shown as being crucial for reducing the spread of disease. We did not record any disease outbreak and registered only one positive case during the peri-transplant period at our facility. The most common comorbidities were arterial hypertension or other cardiovascular disease, type 2 diabetes and renal impairment. Two-thirds of positive patients were on first line treatment. Hypogammaglobulinemia did not prove to be a risk factor for a severe COVID-19 course and we did not observe it to be an obstacle for seroconversion. Conclusion: Preventive measures are significant for reducing the spread of disease, especially in haematology centres. In our single centre experience, we report a mortality of 14%. Although we report a relatively small cohort and much remains yet to be clarified, our results can even now be implemented in daily practice.
Keywords:
Multiple myeloma – Immune suppression – haemato-oncology – COVID-19 – coronavirus – immunoparesis
Sources
1. Robilotti EV, Babady NE, Mead PA, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020; 26 (8): 1218–1223.
2. Malard F, Genthon A, Brissot E, et al. COVID--19 outcomes in patients with hematologic disease. Bone Marrow Transplant. 2020; 55 (11): 2180–2184.
3. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21 (3): 335–337.
4. Gao Y, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID‐19 patients: A review. Allergy. 2021; 76 (2): 428–455.
5. Al‐Shamsi HO, Alhazzani W, Alhuraiji A, et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID ‐19) pandemic: An international collaborative group. The Oncologist [online]. červen 2020 [citován 11. březen 2021]; 25 (6). Dostupné z: https: //onlinelibrary.wiley.com/ doi/10.1634/theoncologist.2020-0213.
6. Brandes AA, Ardizzoni A, Artioli F, et al. Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. Future Oncol. 2020; 16 (20): 1433–1439.
7. Gandhi M, Egner W, Sizer L, et al. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplant. 2001; 28 (8): 775–781.
8. Lo W, Whimbey E, Elting L, Couch R, Cabanillas F, Bodey G. Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. Eur J Clin Microbiol Infect Dis. 1993; 12 (10): 778–782.
9. Frerichs KA, Bosman PWC, van Velzen JF, et al. Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients. Haematologica. 2020; 105 (6): e302–e306.
10. Robertson JD, Nagesh K, Jowitt SN, et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer. 2000; 82 (7): 1261–1265.
11. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12 (1): 36–44.
12. Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020; 136 (25): 2881–2892.
13. Kim JS, Lee KH, Kim GE, et al. Clinical characteristics and mortality of patients with hematologic malignancies and COVID-19: a systematic review. Eur Rev Med Pharmacol Sci. 2020; 24 (22): 11926–11933.
14. Wang B, Van Oekelen O, Mouhieddine TH, et al. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. J Hematol Oncol. 2020; 13 (1): 94.
15. Hultcrantz M, Richter J, Rosenbaum CA, et al. COVID-19 Infections and clinical outcomes in patients with multiple myeloma in New York City: A cohort study from five academic centers. Blood Cancer Discov. 2020; 1 (3): 234–243.
16. Glenthøj A, Jakobsen LH, Sengeløv H, et al. SARS‐CoV‐2 infection among patients with haematological disorders: Severity and one‐month outcome in 66 Danish patients in a nationwide cohort study. Eur J Haematol. 2021; 106 (1): 72–81.
17. https: //www.ashresearchcollaborative.org/s/covid-19-registry/data-summaries. Navštíveno 1.2.2021 v 17: 40.
18. Tahaghoghi-Hajghorbani S, Zafari P, Masoumi E, et al. The role of dysregulated immune responses in COVID-19 pathogenesis. Virus Res. 2020; 290: 198197.
19. Afzal A. Molecular diagnostic technologies for COVID-19: Limitations and challenges. J Adv Res. 2020; 26: 149–159.
20. Gauger PC, Vincent AL. Serum virus neutralization assay for detection and quantitation of serum neutralizing antibodies to influenza A virus in swine. In: Spackman E, editor. Animal influenza virus [online]. New York, NY: Springer US; 2020 [citován 11. březen 2021]. s. 321–33. (Methods in Molecular Biology; roč. 2123). Dostupné z: http: //link.springer.com/10.1007/978-1-0716-0346-8_23.
21. Chang MC, Park Y-K, Kim B-O, Park D. Risk factors for disease progression in COVID-19 patients. BMC Infect Dis. 2020; 20 (1): 445.
22. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061.
23. Ebinger JE, Achamallah N, Ji H, et al. Pre-existing traits associated with Covid-19 illness severity. Kou YR, editor. PLOS ONE. 2020; 15 (7): e0236240.
24. Suleyman G, Fadel RA, Malette KM, et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit. JAMA Netw Open. 2020; 3 (6): e2012270.
25. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020; 323 (16): 1574.
26. https: //www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
27. Hoiland RL, Fergusson NA, Mitra AR, et al. The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19. Blood Adv. 2020; 4 (20): 4981–4989.
28. Silva-Filho JC, Melo CGF de, Oliveira JL de. The influence of ABO blood groups on COVID-19 susceptibility and severity: A molecular hypothesis based on carbohydrate-carbohydrate interactions. Med Hypotheses. 2020; 144: 110155.
29. Susek KH, Gran C, Ljunggren H, Alici E, Nahi H. Outcome of COVID‐19 in multiple myeloma patients in relation to treatment. Eur J Haematol. 2020; 105 (6): 751–754.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2021 Issue 4
Most read in this issue
- Hypereosinophilia
- Congenital neutropenia in children and adults
- Neuro-immune interactions in the oncogenesis of multiple myeloma and their therapeutical relevance
- West Nile fever in the background of the COVID-19 pandemic